High-Dose Osimertinib for CNS progression in EGFR+ NSCLC: A Multi-Institutional Experience

MLA

Piper-Vallillo, A. J., et al. “High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.” JTO Clinical and Research Reports, no. Preprints, Jan. 2022. EBSCOhost, https://doi.org/10.1016/j.jtocrr.2022.100328.

APA

Piper-Vallillo, A. J., Rotow, J. K., Aredo, J. V., Shaverdashvili, K., Jia, L., Carlisle, J., Husain, H., Muzikansky, A., Heist, R., Rangachari, D., Ramalingam, S. S., Wakelee, H. A., Yu, H. A., Sequist, L., Bauml, J. M., Neal, J. W., & Piotrowska, Z. (2022). High-Dose Osimertinib for CNS progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clinical and Research Reports, Preprints. https://doi.org/10.1016/j.jtocrr.2022.100328

Chicago

Piper-Vallillo, A.J., Julia K. Rotow, Jacqueline V. Aredo, Khvaramze Shaverdashvili, Luo Jia, Jennifer Carlisle, Hatim Husain, et al. 2022. “High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.” JTO Clinical and Research Reports, no. Preprints (January). doi:10.1016/j.jtocrr.2022.100328.